Motoi Odani Selected Research

Vomiting

10/2017	A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
1/2017	A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients .

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Motoi Odani Research Topics

Disease

5	Secondary Hyperparathyroidism 12/2018 - 01/2017
2	Chronic Renal Insufficiency 12/2018 - 04/2018
2	Vomiting 10/2017 - 01/2017
1	Neoplasms (Cancer) 01/2020
1	Sepsis (Septicemia) 01/2020
1	Nausea 10/2017
1	Nasopharyngitis 01/2017

Drug/Important Bio-Agent (IBA)

4	etelcalcetide hydrochlorideIBA 04/2018 - 01/2017
2	Calcium-Sensing ReceptorsIBA 07/2017 - 01/2017
1	Immune Checkpoint InhibitorsIBA 01/2020
1	NivolumabIBA 01/2020
1	CalciumIBA 01/2017

Therapy/Procedure

4	Renal Dialysis (Hemodialysis) 12/2018 - 01/2017
1	Therapeutics 04/2018